Bleeding Events After Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
21 02 2023
Historique:
received: 25 10 2022
accepted: 21 11 2022
entrez: 15 2 2023
pubmed: 16 2 2023
medline: 18 2 2023
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR) has gained over time a major reduction in procedural complications. Despite this, clinically relevant bleeding still occurs in a non-negligible proportion of patients and adversely affects prognosis. Patients with severe aortic stenosis are at heightened risk for spontaneous bleeding due to advanced age and a high comorbidity burden. Also, procedural factors and antithrombotic management contribute to define individual bleeding susceptibility. Bleeding prevention represents an emerging area for improving patient care. Because of the tight hemorrhagic/ischemic balance, a tailored approach based on individual bleeding-risk profile, such as a less invasive antithrombotic regimen or appropriate diagnostic preprocedural evaluation, should be pursued to avoid bleeding events. This review aims to provide an in-depth overview of bleeding events in the TAVR field, including definitions, timing and the extent of risk, and clinical impact, as well as updates on antithrombotic management and its potential influence on bleeding complications.

Identifiants

pubmed: 36792284
pii: S0735-1097(22)07622-7
doi: 10.1016/j.jacc.2022.11.050
pii:
doi:

Substances chimiques

Fibrinolytic Agents 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

684-702

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Nuche has received a research grant from the “Fundación Alfonso Martín Escudero” (Madrid, Spain). Dr Rodés-Cabau has received institutional research grants and speaker/consultant fees from Edwards Lifesciences and Medtronic. Dr Rodés-Cabau holds the research chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Marisa Avvedimento (M)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Jorge Nuche (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Julio I Farjat-Pasos (JI)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodés-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH